LIFE-B:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund UnHedged Units (CAD)

ETF | Others |

Last Closing

CAD 25.5

Change

0.00 (0.00)%

Market Cap

CAD 0.01B

Volume

402.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

+0.10 (+0.37%)

CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

-0.01 (-0.02%)

CAD 4.83B
PHYS-U:CA Sprott Physical Gold Trust

+0.02 (+0.11%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.41 (+0.60%)

CAD 4.54B
HXT-U:CA Horizons S&P/TSX 60 Index ETF

-0.19 (-0.46%)

CAD 3.92B
XEQT:CA iShares Core Equity Portfolio

+0.15 (+0.49%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

+0.10 (+0.45%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

+0.17 (+1.72%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.03 (-0.14%)

CAD 2.78B
NUBF:CA NBI Unconstrained Fixed Income..

-0.14 (-0.67%)

CAD 2.52B

ETFs Containing LIFE-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.19% 60% D- 59% D-
Dividend Return 0.67% 51% F 24% F
Total Return 7.86% 62% D 57% F
Trailing 12 Months  
Capital Gain 6.61% 47% F 50% F
Dividend Return 2.01% 80% B- 43% F
Total Return 8.61% 49% F 47% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.97% 57% F 49% F
Dividend Return 2.10% 58% F 43% F
Total Return 0.13% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 5.45% 69% C- 86% B+
Risk Adjusted Return 38.48% 70% C- 61% D-
Market Capitalization 0.01B 23% F 9% A-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.